Phase III Study Of Avastin(R) In Advanced Pancreatic Cancer Does Not Meet Primary Endpoint
Wed, 28 Jun 2006 06:00 AM EST
... Genentech, Inc. (NYSE: DNA) today announced that a Phase III trial ofAvastin(R) (bevacizumab) in combination with gemcitabine chemotherapy asfirst-line treatment for advanced pancreatic cancer did not meet itsprimary endpoint of overall survival. [click link for full article] ...
Related Topics
- Bevacizumab Injection
- Pancreatic Cancer
- Tarceva
- Primary
- Clinical Trials
- Primary Care
- Prostate Cancer
- Cancers
- Antithrombin III
- Liver Cancer
- Thyroid Cancer
- Metastatic Cancer
- Cancer Alternative Therapy
- Pulmonary Hypertension
- Pancreatic Insufficiency
- Bile Duct Cancer
- Hepatocellular
- Cancer
- Familial Dysautonomia
- Pancreatic Cancer, Childhood

Not Signed In -


